Nomura maintains a Buy rating on HENGRUI PHARMA despite trimming the target price from HKD94.54 to HKD87.49 due to expectations of revenue growth that, while below market expectations for 4Q25, still indicates a positive trajectory. The firm anticipates a 7% year-over-year increase in revenue for 4Q25, driven by a 14% growth in drug sales and significant collaboration revenue from a licensing agreement with GSK. Additionally, Nomura projects substantial growth in net profit attributable to shareholders, with a 32% increase expected for 4Q25 and a 30% increase projected for 2026, both exceeding market expectations. The anticipated expansion in gross and operating profit margins further supports the positive outlook, justifying the Buy rating.

Morgan Stanley

Overweight

maintain

$86 -> $92

2026-01-27

Reason

Morgan Stanley

Price Target

$86 -> $92

2026-01-27

maintain

Overweight

Reason

Morgan Stanley lowered its total revenue forecasts for HENGRUI PHARMA for 2025-2027 by 2.1%, 3.7%, and 1.8% due to lower commercial development income from GlaxoSmithKline (GSK) assets and a decline in contributions from the generic drug business. This was partially offset by higher forecasts for innovative drug sales. Additionally, the broker reduced its net profit forecasts by 7.4%, 8.9%, and 6.5%, respectively. Despite these adjustments, Morgan Stanley raised its target price for HENGRUI PHARMA from $86 to $92 and maintained an Overweight rating, reflecting a positive outlook based on the adjusted valuation and currency assumptions.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01276

Unlock Now

Valuation Metrics

The current forward P/E ratio for (01276.HK) is 44.94, compared to its 5-year average forward P/E of 52.17. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

52.17

Current PE

44.94

Overvalued PE

61.02

Undervalued PE

43.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

41.77

Current EV/EBITDA

32.95

Overvalued EV/EBITDA

49.27

Undervalued EV/EBITDA

34.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.10

Current PS

11.02

Overvalued PS

12.66

Undervalued PS

9.54

Financials

AI Analysis

Annual

Quarterly

Whales Holding 01276

Trading Trends

People Also Watch

Frequently Asked Questions

What is (01276) stock price today?

The current price of 01276 is 64.5 USD — it has increased 0.78

What is (01276)'s business?

What is the price predicton of 01276 Stock?

Wall Street analysts forecast 01276 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01276 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (01276)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (01276)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (01276). have?

(01276) has 0 emplpoyees as of March 03 2026.

What is (01276) market cap?

Today 01276 has the market capitalization of 0.00 USD.

01276 Overview